Clinical Trial Update: A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL. [Phase 1]

View source ↗

Summary

Phase 1 study update of TRS005 in relapsed/refractory CD20-positive B-cell Non-Hodgkin Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd20-positive B-cell Non-hodgkin Lymphoma

Drugs mentioned

• TRS005 (TRS005)

Snippet

Sponsor: Zhejiang Teruisi Pharmaceutical Inc. | Conditions: CD20-positive B-cell Non-Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING